Current investigations into Glypican-3, a highly specific antigen in HCC, have demonstrated that BsAbs targeting both Glypican-3 and CD3 can significantly enhance cytotoxic immune responses against tumor cells [105]. This evidence concerns the gene GPC3 and hepatocellular carcinoma.